Inclisiran (Leqvio) — CPB 1004 | AETNA Coverage Update

Aetna modified CPB 1004 covering inclisiran (Leqvio) for commercial plans, effective November 11, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its inclisiran coverage policy under CPB 1004 Aetna system. The change affects claims billed with HCPCS code J1306 (injection, inclisiran, 1 mg) and CPT 96372 for subcutaneous injection administration. If your practice manages high-risk cardiovascular patients or HeFH cases and bills Aetna commercial plans, this policy governs every inclisiran claim you submit in 2025 and beyond.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Inclisiran (Leqvio) — CPB 1004
Policy Code	CPB 1004
Change Type	Modified
Effective Date	November 11, 2025
Impact Level	High
Specialties Affected	Cardiology, Lipidology, Internal Medicine, Endocrinology, Primary Care
Key Action	Verify LDL-C thresholds and statin history documentation are in the patient chart before submitting precertification for J1306

---

Aetna Inclisiran Coverage Criteria and Medical Necessity Requirements 2025

Precertification is required on every inclisiran claim under this coverage policy. No exceptions. Call Aetna at (866) 752-7021 or fax (888) 267-3277 before administering the drug. Missing that step will trigger a claim denial regardless of how clean the rest of the claim is.

Aetna routes all inclisiran prior authorization requests through its Gene-based, Cellular & Other Innovative Therapies (GCIT) team. This is the same dedicated review unit Aetna uses for other high-cost specialty therapeutics. Expect more scrutiny than a standard PA review — have your clinical documentation ready before you call.

Pathway 1: ASCVD History

The first path to medical necessity approval requires documented clinical atherosclerotic cardiovascular disease (ASCVD). Your chart must show ASCVD history, a qualifying LDL-C level, and prior statin therapy — all three.

LDL-C thresholds under Pathway 1:

#	Covered Indication Copy
1	LDL-C ≥ 70 mg/dL, or
2	LDL-C ≥ 55 mg/dL plus multiple ASCVD events or high-risk conditions (age 65+, familial hypercholesterolemia, diabetes, chronic kidney disease, or history of congestive heart failure)

Statin requirement under Pathway 1:

The member must have at least three months of high-intensity statin therapy on record. If the patient can't tolerate high-intensity dosing, moderate-intensity statin use is acceptable. If the patient has a documented contraindication or intolerance to statins entirely, that satisfies this criterion — but you need the documentation to prove it.

Pathway 2: Untreated LDL-C ≥ 190 mg/dL

The second path applies to patients with severely elevated baseline cholesterol. This covers cases without a secondary cause — think primary hypercholesterolemia or familial hypercholesterolemia (ICD-10 E78.01).

Criteria under Pathway 2:

#	Covered Indication Copy
1	Untreated (pre–lipid-lowering therapy) LDL-C ≥ 190 mg/dL, and
2	Current LDL-C ≥ 100 mg/dL, and
3	At least three months of high-intensity statin therapy — or documented contraindication/intolerance

Both pathways require the statin step. There's no shortcut around it, and Aetna's prior authorization reviewers will look for it.

Continuation of Therapy

Continuation approval is more straightforward. Aetna considers ongoing inclisiran therapy medically necessary when the member has achieved or maintained an LDL-C reduction. "LDL-C is now at goal" or "robust lowering of LDL-C" — Aetna's own language — are the benchmarks. Document the LDL-C trend at each visit. That lab data is your reimbursement insurance when the renewal PA comes due.

---

Aetna Inclisiran Exclusions and Non-Covered Indications

Aetna considers all inclisiran indications outside the two pathways above to be experimental, investigational, or unproven. That's a broad exclusion. If a patient presents with elevated Lipoprotein(a) alone — ICD-10 E78.41 — and doesn't meet ASCVD or high-baseline LDL criteria, the claim will not be covered under this policy.

The same goes for pure hypercholesterolemia (E78.00) without the supporting LDL-C thresholds and statin history. Diagnosis code alone doesn't get you there. The clinical criteria have to line up.

---

Coverage Indications at a Glance

---

Aetna Inclisiran Billing Guidelines and Action Items 2025

This is where the rubber meets the road. The policy's criteria are specific, and Aetna's GCIT reviewers are trained to find gaps. Here's what your billing team needs to do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Inclisiran Under CPB 1004

HCPCS Codes Covered When Selection Criteria Are Met

Code	Type	Description Copy
J1306	HCPCS	Injection, inclisiran, 1 mg

CPT Codes Related to CPB 1004

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E78.41	Elevated Lipoprotein(a)

A few things worth knowing about how these codes interact. J1306 is your primary billing code for inclisiran — dose it correctly per the package insert (284 mg/1.5 mL per injection). CPT 83721 is the stronger supporting lab code when you need to prove a specific LDL-C number; it's a direct measurement, not a calculated value. Aetna reviewers may scrutinize calculated LDL values from a standard lipid panel differently than a direct LDL result. When precision matters — and it does at the 70 mg/dL and 55 mg/dL thresholds — use 83721.

E78.41 is in the policy, but treat it as a secondary code. Listing elevated Lp(a) as the primary diagnosis on an inclisiran claim will draw scrutiny. Pair it with an ASCVD code and a qualifying LDL-C diagnosis when it appears at all.

---